Table 2

Summary of biomarker studies and other topics

Abstract ID and type	Study design (sample size)	Biomarker^†	Preliminary results
Abstracts presented at ASCO23
5513 (poster session)53	Biomarker analysis of a phase I study (NCT04516447) (n=80)	Cyclin E1	High expression of cyclin E1 is correlated with enhanced objective response rate and improved progression-free survival in patients treated with the WEE1 inhibitor azenosertib (ZN-c3) in combination with chemotherapy
5557 (poster session)54	Biomarker analysis of a phase II study (NCT02203513) (n=39)	Innate immunity	Innate immunity may be involved in modulating response of the CHK1 inhibitor prexasertib. Resistance to prexasertib may be associated with peripheral immunosuppressive cells and lower immunocompetence of the innate immune system of platinum-resistant ovarian cancer
3093 (poster session)55	Pharmacokinetic analysis of a phase I trial (PemBOv trial; NCT03596281) (n=44)	Circulating levels of bevacizumab	Higher plasma trough levels of bevacizumab showed a positive association with both objective response rate and clinical benefit in platinum-resistant ovarian cancer patients who received a combination treatment of bevacizumab and pembrolizumab, with or without pegylated liposomal doxorubicin (PLD)
5578 (poster session)56	Retrospective real-world cohort study (n=91)	–	Patients who experienced disease progression following treatments with PARP inhibitors (olaparib and niraparib) had poor response to subsequent platinum-based chemotherapy Resistance to PARP inhibitors may confer resistance to platinum-based chemotherapy and may be a surrogate of response
e17585 (publication only)57	Cost-effective analysis (na)	–	The analysis of cost-effectiveness for rotational intraperitoneal aerosol chemotherapy (RIPAC) in patients with platinum-resistant ovarian cancer revealed that the total medical costs for three cycles of palliative chemotherapy completion using PLD, gemcitabine, topotecan, and clinicians’ choice of regimens were US$15 267, US$9013, US$16 144, and US$12 631, respectively The corresponding QALYs for each regimen were 0.633, 0.553, 0.783, and 0.65
e17574 (publication only)58	Retrospective real-world cohort study (n=172)	–	Patients with recurrent disease who received PARP inhibitors as maintenance therapy after first-line chemotherapy were more likely to have platinum-resistant ovarian cancer independently of the treatment duration
TPS5619 (poster session)59	Biomarker analysis of a phase II study (NCT05114421) (n=30)	T cell populations	The study aims to uncover immunologic factors associated with response with efficacy of pembrolizumab and lenvatinib as single agents or combined in platinum-resistant ovarian cancer patients Dynamic changes in the tumor microenvironment of the peritoneum will be studied using multichannel flow cytometry
e17540 (publication only)60	Biomarker/factor analysis of a randomized study (no study phase or registration number were provided) (n=40)	CA125, and/or peritoneal effusion	Sensitivity of p62/SQSTM1-encoding plasmid combined with gemcitabine may be associated with initial high level of CA125 and/or peritoneal effusion
e14573 (publication only)61	Preclinical (ex vivo)	–	THEO-260 is a novel oncolytic virus therapy that demonstrated antitumor efficacy in platinum-resistant ovarian cancer with complete reduction of tumor volume in subcutaneous and intraperitoneal animal models
Abstracts presented at ESMO23
776P (poster session)62	Prospective cohort	JAK-STAT	Activity of JAK-STAT signaling pathway is lower in patients with refractory ovarian cancer Responders to platinum had higher expression of interferon pathway genes
1O (oral abstract session)63	Preclinical (in vitro and in vivo)	CircIGF1R_0001	CircIGF1R_0001 overexpression mediates resistance to platinum and sensitivity to PARP inhibitors
2141P (poster session)64	Systematic review	–	Patients with platinum-resistant ovarian cancer experience a significant burden of symptoms such as gastrointestinal disturbances, pain, fatigue, emotional distress, and poor functioning, with existing treatments showing limited improvement in health-related QoL

*Based on clinical trial record on clinicaltrials.gov database, the study is recruiting, and it included 10 patients at the time of submission. ^†When applicable. na, not applicable.
CA125, cancer antigen 125; CHK1, checkpoint kinase 1 ; JAK/STAT, Janus kinase/signal transducer and activator of transcription; PARP, poly-ADP ribose polymerase; PLD, pegylated liposomal doxorubicin; QALYs, quality-adjusted life years; QoL, quality of life; RIPAC, rotational intraperitoneal aerosol chemotherapy; SQSTM1, sequestosome 1.